1-12 of 12
Chi-Chung Li
Close
Save search
Sort by
Journal Articles

Cytokine Release Syndrome: Trends with T Cell Engaging Bispecifics from a Systematic Review of Licensing Applications

Free
Kendra Radtke, Brendan C Bender, Zao Li, David C. Turner, Sumi Roy, Anton Belousov, Chi-Chung Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 5798.
https://doi.org/10.1182/blood-2024-193916
Published: 2024
Journal Articles

Population Pharmacokinetics and CD20 Binding Dynamics for Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL)

Free
Brendan C Bender, Chi-Chung Li, Mathilde Marchand, David C. Turner, Feifei Li, Shweta Vadhavkar, Bei Wang, Rong Deng, James Lu, Jin Jin, Chunze Li, Shen Yin, Michael C. Wei, Pascal Chanu
Journal: Blood
Blood (2023) 142 (Supplement 1): 2810.
https://doi.org/10.1182/blood-2023-182086
Published: 2023
Journal Articles

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

Free
L. Elizabeth Budde, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta Nastoupil, Michael C. Wei, Shen Yin, Michelle Y. Doral, Chi-Chung Li, Huang Huang, Raluca Negricea, Elicia Penuel, Carol O'Hear, Nancy L. Bartlett
Journal: Blood
Blood (2021) 138 (Supplement 1): 127.
https://doi.org/10.1182/blood-2021-145872
Published: 2021
Journal Articles

Development of a Predictive Model for Cytokine Release Syndrome to Inform Risk Stratification and CRS Management Following Immunotherapy

Free
Krishna V. Komanduri, Anton Belousov, Michelle Byrtek, Antonia Kwan, David Perez-Callejo, Chi-Chung Li, David Carlile, Bruce McCall, Tina Nielsen, Emily C. Piccione
Journal: Blood
Blood (2021) 138 (Supplement 1): 1459.
https://doi.org/10.1182/blood-2021-147303
Published: 2021
Journal Articles

Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study

Free
Nancy L. Bartlett, Pratyush Giri, L. Elizabeth Budde, Stephen J. Schuster, Sarit Assouline, Matthew J. Matasar, Sung-Soo Yoon, Miguel Canales, Norma C. Gutierrez, Keith Fay, Chan-Yoon Cheah, Paula Marlton, Volker Wiebking, Shen Yin, Iris To, Chi-Chung Li, Huang Huang, Mingzhu Zhou, Elicia Penuel, Carol O'Hear, Laurie H. Sehn
Journal: Blood
Blood (2021) 138 (Supplement 1): 3573.
https://doi.org/10.1182/blood-2021-147937
Published: 2021
Journal Articles

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

Free
Matthew J Matasar, MD, Chan Yoon Cheah, MBBS, Dok Hyun Yoon, Sarit E Assouline, MD MSc, Nancy L. Bartlett, MD, Matthew Ku, Pratyush Giri, Anna Johnston, MBBS (Hons 1), FRACP, FRCPA, Ian W. Flinn, MD PhD, Andre H. Goy, MD, Dimitrios Tzachanis, MD PhD, Carol O'Hear, Shen Yin, Iris To, Kati Sarouei, Chi-Chung Li, Brendan C. Bender, Elicia M. Penuel, Huang Huang, L. Elizabeth Budde
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-135818
Published: 2020
Journal Articles

Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial

Free
Sarit E Assouline, MD MSc, Won Seog Kim, MD PhD, Laurie H. Sehn, MDMPH, Stephen J. Schuster, MD, Chan Yoon Cheah, MBBS, Loretta J. Nastoupil, MD, Mazyar Shadman, Sung-Soo Yoon, MD PhD, Matthew J Matasar, MD, Catherine Diefenbach, MD, Gareth P. Gregory, Nancy L. Bartlett, MD, Michael C. Wei, Michelle Y. Doral, Shen Yin, Raluca Negricea, Chi-Chung Li, Elicia M. Penuel, Huang Huang, L. Elizabeth Budde
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–44.
https://doi.org/10.1182/blood-2020-135839
Published: 2020
Journal Articles

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

Free
Genevive Hernandez, PhD, Ling-Yuh Huw, PhD, Anton Belousov, PhD, Deanna Wilson, MS, Hartmut Koeppen, MD PhD, Ron McCord, PhD, Kun Peng, PhD, Nancy L Bartlett, MD, Lihua E Budde, MD PhD, Sarit Assouline, MD, Loretta J. Nastoupil, MD MSc, Dok Hyun Yoon, MD PhD, Matthew J Matasar, MD, Brendan Bender, PhD, Antonia Kwan, MD PhD MRCPCH, Chi-Chung Li, PhD, Carol O'Hear, MD PhD, Shen Yin, PhD, Michael C Wei, MD PhD, Joanne I Adamkewicz, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1585.
https://doi.org/10.1182/blood-2019-123933
Published: 2019
Journal Articles

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

Free
Chi-Chung Li, PhD, Brendan Bender, PhD, Shen Yin, PhD, Zao Li, PhD, Cindy Zhang, MS, Genevive Hernandez, PhD, Antonia Kwan, MD PhD MRCPCH, Laura Sun, PhD, Joanne I Adamkewicz, PhD, Hong Wang, MD PhD DABT, Natalie Dimier, PhD, Sue-Zen Lim, BPharm, Carol O'Hear, MD PhD, Laurie H Sehn, MD, Ian W. Flinn, MD PhD, Sung-Soo Yoon, MD PhD, Lihua E Budde, MD PhD, Chunze Li, PhD, Michael C Wei, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1285.
https://doi.org/10.1182/blood-2019-123961
Published: 2019
Journal Articles

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Free
Stephen J Schuster, MD, Nancy L Bartlett, MD, Sarit Assouline, MD, Sung-Soo Yoon, MD PhD, Francesc Bosch, MD PhD, Laurie H Sehn, MD, Chan Y. Cheah, Mazyar Shadman, MD MPH, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Matthew Ku, MBBS, FRACP, FRCPA, PhD, Michael C Wei, MD PhD, Shen Yin, PhD, Antonia Kwan, MD PhD MRCPCH, Kasra Yousefi, MSc, Genevive Hernandez, PhD, Chi-Chung Li, PhD, Carol O'Hear, MD PhD, Lihua E Budde, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 6.
https://doi.org/10.1182/blood-2019-123742
Published: 2019
Journal Articles

An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk

Free
Catherine Diefenbach, MD, Sarit Assouline, MD, Francesc Bosch, MD PhD, Chan Y. Cheah, Won Seog Kim, MD PhD, Matthew J Matasar, MD, Carlos Panizo, MD PhD, Dok Hyun Yoon, MD PhD, Brendan Bender, PhD, Genevive Hernandez, PhD, Chi-Chung Li, PhD, Bruce McCall, MD, Carol O'Hear, MD PhD, Michael C Wei, MD PhD, Shen Yin, PhD, Kasra Yousefi, MSc, Antonia Kwan, MD PhD MRCPCH, Loretta J. Nastoupil, MD MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 4728.
https://doi.org/10.1182/blood-2019-123757
Published: 2019
Journal Articles

Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study

Free
Lihua E Budde, Laurie H Sehn, MDMPH, Sarit Assouline, Ian W. Flinn, MD PhD, Iris Isufi, MD, Sung-Soo Yoon, MD PhD, Won-Seog Kim, Matthew J Matasar, Loretta J. Nastoupil, MD, Raoul Santiago, Youngil Koh, MD PhD, Genevive Hernandez, Chi-Chung Li, Priya R Kulkarni, Bruce McCall, Scott McClellan, Shen Yin, Vinita Gupta, Yu-Waye Chu, Nancy L. Bartlett, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 399.
https://doi.org/10.1182/blood-2018-99-118344
Published: 2018